Vir Biotechnology (Switzerland)
ORCID: 0000-0002-5797-1364Publishes on SARS-CoV-2 and COVID-19 Research, Animal Virus Infections Studies, Viral gastroenteritis research and epidemiology. 304 papers and 39.7k citations.
Add your photo, update your bio, and get notified when your ranking changes.
The isolation of broadly neutralizing antibodies against influenza A viruses has been a long-sought goal for therapeutic approaches and vaccine design. Using a single-cell culture method for screening large numbers of human plasma cells, we isolated a neutralizing monoclonal antibody that recognized the hemagglutinin (HA) glycoprotein of all 16 subtypes and neutralized both group 1 and group 2 influenza A viruses. Passive transfer of this antibody conferred protection to mice and ferrets. Complexes with HAs from the group 1 H1 and the group 2 H3 subtypes analyzed by x-ray crystallography showed that the antibody bound to a conserved epitope in the F subdomain. This antibody may be used for passive protection and to inform vaccine design because of its broad specificity and neutralization potency.
Coming soon — researchers in similar fields and career stages